Summary (tl;dr)

More than 11,000 bottles of Chlorthalidone, a blood pressure medication distributed by Rising Pharma Holdings, Inc., have been voluntarily recalled due to a failure to meet dissolution specifications, meaning the tablets may not work as intended in the body.

Essential Background

Chlorthalidone is a widely used diuretic, also known as a "water pill," prescribed to treat high blood pressure (hypertension) and reduce fluid retention caused by conditions such as heart, kidney, or liver disease. It helps the kidneys remove excess fluid and salt from the blood, which in turn helps to lower blood pressure. If high blood pressure remains untreated, it can lead to serious health issues, including stroke, heart failure, and kidney damage.

The Full Story

Rising Pharma Holdings, Inc. initiated a voluntary nationwide recall on June 5, 2026, for 11,460 bottles of Chlorthalidone Tablets, USP, 25 mg. The affected medication, manufactured by Inventia Healthcare Limited in India, failed "dissolution specifications" during testing. This failure indicates that the tablets may not dissolve correctly in the body, potentially rendering them less effective or delivering an incorrect dosage. The recall impacts specific batches (RISA24001 and RISB24002) in both 100-count and 1,000-count bottles, all with an expiration date of April 2027. As of recent reports, the U.S. Food and Drug Administration (FDA) has not yet assigned a recall classification (such as Class I or II) to this event.

Why It Matters

This recall is significant because ineffective blood pressure medication can lead to uncontrolled hypertension, increasing patients' risk of serious cardiovascular events like stroke, heart attacks, or kidney failure. Patients relying on Chlorthalidone to manage their conditions may not be receiving the full therapeutic benefit, which could jeopardize their health. Healthcare providers advise against abruptly discontinuing blood pressure medication without consulting a doctor or pharmacist, emphasizing the importance of seeking guidance for safe alternatives. This event also highlights ongoing concerns about quality control within the pharmaceutical supply chain, particularly for widely used generic drugs.

Geographic Location

• East Brunswick, Middlesex County, New Jersey, United States (distribution of recalled medication by Rising Pharma Holdings, Inc.)
• India (manufacturing of recalled medication by Inventia Healthcare Limited)